Developing research highlights the clinical impact of glucagon-like peptide-1 receptor agonists (GLP-1RA), including their potential role in cancer risk reduction and skin ageing.
A study published in Annals of Oncology displayed that GLP-1RA usage was associated with a significantly lower short-term incidence of obesity-associated cancers among obese, nondiabetic patients. After matching more than 80,000 GLP-1 users with a similar number of patients who received diet and exercise counselling, researchers reported a 41% lower risk of obesity-associated cancers over a median follow-up period of two years.
Separately, a study published in Dermatologic Surgery examined subcutaneous adipose tissue in GLP-1 patients. Analysis of 10 baseline adipose tissue samples demonstrated a statistically significant, approximately four-fold reduction in adipose-derived stem-cell counts (ADSCs) in the GLP-1 group compared with controls. Authors describe this as the first in vivo human study to demonstrate a marked reduction in ADSCs in GLP-1-treated patients, suggesting that selective ADSC depletion of may contribute to accelerated skin ageing changes in this population.